This study is the first to comprehensively assess NrCAM as a circulating biomarker in pregnancies complicated by fetal growth restriction and/or preeclampsia across multiple, independent cohorts.

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...

VEGF-C and VEGFR-3 are two major regulatory molecules of lymphangiogenesis. β-Elemene could restrain lymphangiogenesis in a dose-dependent pattern by manipulating the VEGF-C and VEGFR-3, which could ...

Cabozantinib plus atezolizumab, a novel drug combination that does not directly target androgen receptor signalling, could be a useful treatment option for patients with mCRPC and soft-tissue ...